SEC Comment Letter 0000000000-24-002105 to ENANTA PHARMACEUTICALS INC (ENTA)

ENANTA PHARMACEUTICALS INC
Date: Feb. 26, 2024 · CIK: 0001177648 · Accession: 0000000000-24-002105

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-35839

Date

February 26, 2024

Author

Paul Mellett

Form

UPLOAD

Company

ENANTA PHARMACEUTICALS INC

Letter

United States securities and exchange commission logo February 26, 2024 Paul Mellett Chief Financial Officer Enanta Pharmaceuticals, Inc. 500 Arsenal Street Watertown, MA 02472 Re:Enanta Pharmaceuticals, Inc. Form 10-K for Fiscal Year Ended September 30, 2023 File No. 001-35839 Dear Paul Mellett: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
February 26, 2024
Paul Mellett
Chief Financial Officer
Enanta Pharmaceuticals, Inc.
500 Arsenal Street
Watertown, MA 02472
Re:Enanta Pharmaceuticals, Inc.
Form 10-K for Fiscal Year Ended September 30, 2023
File No. 001-35839
Dear Paul Mellett:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io